Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Natural History of Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Lewis, S. M., Bessler, M., Luzzatto, L., & Dacie, J. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331904 · Cited by 907
MOLECULAR ORGANIZATION AND FUNCTION OF THE COMPLEMENT SYSTEM
Müller-Eberhard, H. J. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.001541 · Cited by 859
Fatigue in cancer patients compared with fatigue in the general United States population
Cella, D., Lai, J., Chang, C., Peterman, A., & Slavin, M. (2002) · Cancer · doi:10.1002/cncr.10245 · Cited by 841
Diagnosis and management of paroxysmal nocturnal hemoglobinuria
Parker, C. (2005) · Blood · doi:10.1182/blood-2005-04-1717 · Cited by 783
Drusen complement components C3a and C5a promote choroidal neovascularization
Nozaki, M., Raisler, B. J., Sakurai, E., Sarma, J. V., Barnum, S. R., Lambris, J. D., Chen, Y., Zhang, K., Ambati, B. K., Baffi, J. Z., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408835103 · Cited by 650
Hillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031688 · Cited by 635
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318817 · Cited by 594
Hillmen, P., Muus, P., Dührsen, U., Risitano, A. M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R. A., Hill, A., et al. (2007) · Blood · doi:10.1182/blood-2007-06-095646 · Cited by 579
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18817 · Cited by 575
Structures of complement component C3 provide insights into the function and evolution of immunity
Janssen, B. J. C., Huizinga, E. G., Raaijmakers, H. C. A., Roos, A., Daha, M. R., Nilsson-Ekdahl, K., Nilsson, B., & Gros, P. (2005) · Nature · doi:10.1038/nature04005 · Cited by 541
Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors
Socié, G., Mary, J.-Y., de Gramont, A., Rio, B., Leporrier, M., Rose, C., Heudier, P., Rochant, H., Cahn, J.-Y., & Gluckman, E. (1996) · The Lancet · doi:10.1016/s0140-6736(95)12360-1 · Cited by 518
Ritis, K., Doumas, M., Mastellos, D., Micheli, A., Giaglis, S., Magotti, P., Rafail, S., Kartalis, G., Sideras, P., & Lambris, J. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4794 · Cited by 489
Keegan, M., König, F., McClelland, R., Brück, W., Morales, Y., Bitsch, A., Panitch, H., Lassmann, H., Weinshenker, B., Rodriguez, M., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67102-4 · Cited by 433
Rollins, S. A., & Sims, P. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3478 · Cited by 405
Holguin, M. H., Fredrick, L. R., Bernshaw, N. J., Wilcox, L. A., & Parker, C. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114172 · Cited by 403
Araten, D. J., Nafa, K., Pakdeesuwan, K., & Luzzatto, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5209 · Cited by 401
Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.
Bessler, M., Mason, P. J., Hillmen, P., Miyata, T., Yamada, N., Takeda, J., Luzzatto, L., & Kinoshita, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06240.x · Cited by 389
Structure of C3b reveals conformational changes that underlie complement activity
Janssen, B. J. C., Christodoulidou, A., McCarthy, A., Lambris, J. D., & Gros, P. (2006) · Nature · doi:10.1038/nature05172 · Cited by 369
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
Wang, Y., Rollins, S. A., Madri, J. A., & Matis, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8955 · Cited by 360
Yamashina, M., Ueda, E., Kinoshita, T., Takami, T., Ojima, A., Ono, H., Tanaka, H., Kondo, N., Orii, T., Okada, N., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010253231707 · Cited by 351
Wang, Y., Hu, Q., Madri, J. A., Rollins, S. A., Chodera, A., & Matis, L. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8563 · Cited by 336
Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
Hall, C., Richards, S., & Hillmen, P. (2003) · Blood · doi:10.1182/blood-2003-01-0009 · Cited by 288
Paroxysmal Nocturnal Hemoglobinuria: Evidence for Monoclonal Origin of Abnormal Red Cells
ONI, S. B., OSUNKOYA, B. O., & LUZZATTO, L. (1970) · Blood · doi:10.1182/blood.v36.2.145.145 · Cited by 275
Canfield, S. M., & Morrison, S. L. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.6.1483 · Cited by 266
Human Antibody Effector Function
Burton, D. R., & Woof, J. M. (1992) · Advances in Immunology · doi:10.1016/s0065-2776(08)60486-1 · Cited by 265
Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays
Moyo, V. M., Mukhina, G. L., Garrett, E. S., & Brodsky, R. A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04992.x · Cited by 264
Nishimura, J.-I., Kanakura, Y., Ware, R. E., Shichishima, T., Nakakuma, H., Ninomiya, H., Decastro, C. M., Hall, S., Kanamaru, A., Sullivan, K. M., et al. (2004) · Medicine · doi:10.1097/01.md.0000126763.68170.46 · Cited by 261
Tao, M. H., Smith, R. I., & Morrison, S. L. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.661 · Cited by 251
Structure of C3b in complex with CRIg gives insights into regulation of complement activation
Wiesmann, C., Katschke, K. J., Yin, J., Helmy, K. Y., Steffek, M., Fairbrother, W. J., McCallum, S. A., Embuscado, L., DeForge, L., Hass, P. E., et al. (2006) · Nature · doi:10.1038/nature05263 · Cited by 250
C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a
Chen, N.-J., Mirtsos, C., Suh, D., Lu, Y.-C., Lin, W.-J., McKerlie, C., Lee, T., Baribault, H., Tian, H., & Yeh, W.-C. (2007) · Nature · doi:10.1038/nature05559 · Cited by 243
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
Hill, A., Hillmen, P., Richards, S. J., Elebute, D., Marsh, J. C., Chan, J., Mojcik, C. F., & Rother, R. P. (2005) · Blood · doi:10.1182/blood-2005-02-0564 · Cited by 212
Verrier, E. D., Shernan, S. K., Taylor, K. M., Van de Werf, F., Newman, M. F., Chen, J. C., Carrier, M., Haverich, A., Malloy, K. J., Adams, P. X., et al. (2004) · JAMA · doi:10.1001/jama.291.19.2319 · Cited by 191
The N-formyl peptide receptors and the anaphylatoxin C5a receptors: An overview
RABIET, M., HUET, E., & BOULAY, F. (2007) · Biochimie · doi:10.1016/j.biochi.2007.02.015 · Cited by 166
Paroxysmal Nocturnal Hemoglobinuria
Rotoli, B., Nafa, K., & Risitano, A. M. (2007) · Principles of Molecular Medicine · doi:10.1007/978-1-59259-963-9_86 · Cited by 161
PIG-A mutations in normal hematopoiesis
Hu, R., Mukhina, G. L., Piantadosi, S., Barber, J. P., Jones, R. J., & Brodsky, R. A. (2005) · Blood · doi:10.1182/blood-2004-04-1472 · Cited by 132
Expressed human immunoglobulin ϰ genes and their hypermutation
Klein, R., Jaenichen, R., & Zachau, H. G. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231231 · Cited by 125
Biesecker, G., & Gomez, C. M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.8.2654 · Cited by 119
C5 gene influences the development of murine myasthenia gravis.
Christadoss, P. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.8.2589 · Cited by 112
Hänsch, G. M., Schönermark, S., & Roelcke, D. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113065 · Cited by 112
Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene
Motoyama, N., Okada, N., Yamashina, M., & Okada, H. (1992) · European Journal of Immunology · doi:10.1002/eji.1830221029 · Cited by 108
Morgan, B. P., Chamberlain-Banoub, J., Neal, J. W., Song, W., Mizuno, M., & Harris, C. L. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03205.x · Cited by 99
Indications for the Immunological Evaluation of Patients with Meningitis
Overturf, G. D. (2003) · Clinical Infectious Diseases · doi:10.1086/345527 · Cited by 99
Enhancement of Platelet Deposition by Cross-Linked Hemoglobin in a Rat Carotid Endarterectomy Model
Olsen, S. B., Tang, D. B., Jackson, M. R., Gomez, E. R., Ayala, B., & Alving, B. M. (1996) · Circulation · doi:10.1161/01.cir.93.2.327 · Cited by 95
Activated platelets in paroxysmal nocturnal haemoglobinuria
Gralnick, H. R., Vail, M., McKeown, L. P., Merryman, P., Wilson, O., Chu, I., & Kimball, J. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05371.x · Cited by 93
Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes
Hill, D. A., Wang, S., Cerhan, J. R., Davis, S., Cozen, W., Severson, R. K., Hartge, P. A., Wacholder, S., Yeager, M., Chanock, S. J., et al. (2006) · Blood · doi:10.1182/blood-2005-01-026690 · Cited by 92
Complement-specific antibodies: Designing novel anti-inflammatories
Matis, L. A., & Rollins, S. A. (1995) · Nature Medicine · doi:10.1038/nm0895-839 · Cited by 85
Smith, R. I. F., Coloma, M. J., & Morrison, S. L. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.5.2226 · Cited by 79
Inhibition of Clotting Factor XIII Activity by Nitric Oxide
Catani, M. V., Bernassola, F., Rossi, A., & Melino, G. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9130 · Cited by 74
Hill, A., Platts, P. J., Smith, A. G., Richards, S. J., Cullen, M. J., Hill, Q. A., Roman, E., & Hillmen, P. (2006) · Blood · doi:10.1182/blood.v108.11.985.985 · Cited by 74
Platonov, A. E. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00440-7 · Cited by 73
Pexelizumab and the APEX AMI Trial
Armstrong, P. W., & Granger, C. B. (2007) · JAMA · doi:10.1001/jama.297.17.1881-b · Cited by 68
Rawstron, A. C., Rollinson, Richards, S. J., Short, English, Morgan, G. J., Hale, G., & Hillmen (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01676.x · Cited by 67
Rother, R. P., Mojcik, C. F., & McCroskery, E. W. (2004) · Lupus · doi:10.1191/0961203303lu1021oa · Cited by 67
Cerebral Ischemic Infarction in Paroxysmal Nocturnal Hemoglobinuria
Audebert, H. J., Planck, J., Eisenburg, M. F., Schrezenmeier, H., & Haberl, R. L. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0871-3 · Cited by 66
Peng, T., Hao, L., Madri, J. A., Su, X., Elias, J. A., Stahl, G. L., Squinto, S. P., & Wang, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22906 · Cited by 62
Thaler, H. T., Luzzatto, L., & Araten, D. J. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-06-0391 · Cited by 60
Wang, H., Jiang, J., Liu, W., Kubelik, D., Chen, G., Gies, D. R., Garcia, B. M., Zhong, R., & Rother, R. P. (2005) · Transplantation · doi:10.1097/01.tp.0000161218.58276.9a · Cited by 54
Sawant‐Mane, S., Clark, M. B., & Koski, C. L. (1991) · Annals of Neurology · doi:10.1002/ana.410290410 · Cited by 53
Protective Role of Nitric Oxide in a Model of Thrombotic Microangiopathy in Rats
Shao, J., Miyata, T., Yamada, K., Hanafusa, N., WADA, T., GORDON, K. L., Inagi, R., Kurokawa, K., Fujita, T., Johnson, R. J., et al. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102088 · Cited by 52
Bottomley, A., Therasse, P., Piccart, M. J., Efficace, F., Coens, C., Gotay, C. C., Wełnicka-Jaśkiewicz, M., Mauriac, L., Dyczka, J., Čufer, T., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70100-5 · Cited by 51
Midkine Is Involved in Kidney Development and in Its Regulation by Retinoids
Vilar, J., Lalou, C., Huyen, J. D. V., Charrin, S., Hardouin, S., Raulais, D., Merlet-Bénichou, C., & Lelièvre-Pégorier, M. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133668 · Cited by 50
Mueller, J. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Squinto, S. P., Matis, L. A., & Evans, M. J. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00042-4 · Cited by 46
Structure and specificities of anti-ganglioside autoantibodies associated with motor neuropathies
Weng, N., Yu‐Lee, L., Sanz, I., Patten, B. M., & Marcus, D. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.7.2518 · Cited by 44
Hill, A., Rother, R. P., & Hillmen, P. (2005) · PubMed · Cited by 44
Kayanoki, Y., Kawata, S., Yamasaki, E., Kiso, S., Inoue, S., Tamura, S., Taniguchi, N., & Matsuzawa, Y. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90127-0 · Cited by 40
Yonemura, Y., Kawakita, M., Koito, A., Kawaguchi, T., Nakakuma, H., Kagimoto, T., Shichishima, T., Terasawa, T., Akagaki, Y., Inai, S., et al. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02546.x · Cited by 33
Okada, N., HARADA, R., & OKADA, H. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb06449.x · Cited by 26
Wislöff, F., Gulbrandsen, N., Hjorth, M., Lenhoff, S., & Fayers, P. M. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00509.x · Cited by 26
Nishimura, J., Phillips, K. L., Ware, R. E., Hall, S. E., Wilson, L., Gentry, T., Howard, T. A., Murakami, Y., Shibano, M., Machii, T., et al. (2001) · Blood · doi:10.1182/blood.v97.10.3004 · Cited by 25
Rother, R. P., Rollins, S. A., Mennone, J., Chodera, A. J., Fidel, S., Bessler, M., Hillmen, P., & Squinto, S. (1994) · Blood · doi:10.1182/blood.v84.8.2604.2604 · Cited by 24
Paroxysmal nocturnal haemoglobinuria
Dacie, J. V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.29 · Cited by 22
Hill, A., Reid, S. A., Rother, R. P., Gladwin, M. T., Collinson, P. O., Gaze, D. C., Lowe, A., Guthrie, A., Sivananthan, M. U., & Hillmen, P. (2006) · Blood · doi:10.1182/blood.v108.11.979.979 · Cited by 14
ROSENFELD, S. I., Jenkins, D., & Leddy, J. P. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.4.981 · Cited by 9
Basic and clinical aspects of autoimmune disorders in peripheral nerves
Willison, H. J. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00607.x · Cited by 8
Muus, P., Luzzatto, L., Rotoli, B., Young, N. S., Schubert, J., Urbano-Ispizúa, Á., Coyle, L. A., DeCastro, C. M., Fu, C., Maciejewski, J. P., et al. (2007) · Leukemia Research · doi:10.1016/s0145-2126(07)70284-9 · Cited by 4
Muus, P., Neste, E. V. D., Duehrsen, U., Elebute, M. O., Browne, P., Urbano-Ispizúa, Á., Coutre, S. E., de Paz, R., Konkle, B. A., Moskovits, T., et al. (2007) · Cited by 1
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620
“The therapeutic monoclonal antibody, Eculizumab, targets human C5 and blocks cleavage by C5 convertases (326).”
BackgroundTerminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne, D. R. W., Merkel, P. A., Schall, T. J., & Bekker, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023386 · Cited by 1,021
RetractedHoward, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
“Eculizumab lacks the ability to bind FcγRs and activate complement, which are common attributes for human IgG2 and IgG4, respectivel”
Background
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.